[18F]AmBF3-PEG7-TOC

**[18F]AmBF3-PEG7-TOC** is a novel radiopharmaceutical agent consisting of a Tyr3-octreotide (TOC) peptide, modified with a polyethylene glycol 7 (PEG7) linker and radiolabeled with the fluorine-18 ([18F]) isotope using an ammoniomethyltrifluoroborate (AmBF3) prosthetic group via bioorthogonal chemistry. The compound is designed for **positron emission tomography (PET) imaging** of tumors that express somatostatin receptors, such as neuroendocrine tumors and AR42J rat pancreatic carcinoma xenografts. Mechanistically, [18F]AmBF3-PEG7-TOC acts as a **somatostatin receptor ligand**, allowing for targeted imaging of receptor-expressing tumors. It demonstrates good in vivo stability, favorable pharmacokinetics (superior tumor uptake, efficient blocking, and lower kidney reabsorption relative to other radiometal-labeled somatostatin analogues), and enables clear tumor visualization in PET/CT studies in animal models. The developer is credited in the primary cited studies as the academic group that created and evaluated the agent in preclinical PET/CT, but specific commercial companies are not mentioned[1][2][3].